Cannabis remains problematic for glaucoma
In any event, glaucoma patients are not rushing to treat themselves with cannabis, according to a July 2016 survey of patients in Colorado and Oregon; fewer than 2% of medical users listed glaucoma as a reason.
Even if cannabinoids are not useful in treating glaucoma themselves, their potent effect on IOP might yield insights leading to better treatments.
But at the moment, research is difficult because federal law has limited the source of cannabis for research to a single site at the University of Mississippi.
This cannabis has lower potency than cannabis sold in state regulated markets, and doesn’t reflect the variety of products on the street.
In August 2016, the DEA announced plans to expand the number of registered marijuana manufacturers, but it’s too early to say how this will effect research in glaucoma, Dr. Radhakrishnan said.